Abstract:BACKGROUND:Although numerous investigators have made efforts to assess prognostic biomarkers of prostate cancer, no biomarker has been recommended for clinical practice. METHODS:According to REMARK (Reporting recommendations for tumor marker prognostic studies) and MISFISHIE (Minimum information specification for in situ hybridization and immunohistochemistry experiments) guidelines, the published articles of immunohistochemistry-based prognostic biomarkers on prostate cancer were extracted and pooled. RESULTS:Ninety-three prognostic biomarkers from 92 high-quality cohort studies were included in this meta-analysis. Our analysis reveals some promising independent prognostic biomarkers, including Ki-67 [all-cause mortality (ACM) HR, 1.85; 95% confidence interval (CI), 1.06-3.25; PSM HR, 1.82; 95% CI, 1.42-2.34; DFS HR, 1.51; 95% CI, 1.31-1.75]; Bcl-2 (ACM HR, 2.14; 95% CI, 1.27-3.58; PSM HR, 1.61; 95% CI, 1.01-2.57; DFS HR, 3.86; 95% CI, 2.14-6.96); CD147 (ACM HR, 2.63; 95% CI, 1.19-5.81; DFS HR, 5.84; 95% CI, 3.41-9.99); COX-2 (PSM HR, 7.6; 95% CI, 0.7-80.1; DFS HR, 7.9; 95% CI, 2.62-23.83); ALDH1A1 (ACM HR, 1.73; 95% CI, 1.163-2.527; PSM HR, 1.05; 95% CI, 1.028-1.107), and FVIII (ACM HR, 1.76; 95% CI, 1.19-2.60; PSM HR, 1.01; 95% CI, 1.01-1.02). CONCLUSIONS:Our analysis identified a subset of biomarkers (Ki-67, Bcl-2, CD147, COX-2, ALDH1A1, and FVIII) that may have prognostic value for predicting the outcome of patients with prostate cancer. IMPACT:These reliable prognostic biomarkers will improve the clinical management of patients with prostate cancer. Cancer Epidemiol Biomarkers Prev; 23(6); 1047-54. ©2014 AACR.

Supplementary Table 3 from Tissue Biomarkers for Prognosis of Prostate Cancer: A Systematic Review and Meta-analysis

Supplementary Table 1 from Tissue Biomarkers for Prognosis of Prostate Cancer: A Systematic Review and Meta-analysis

Supplementary Figure 1C from Tissue Biomarkers for Prognosis of Prostate Cancer: A Systematic Review and Meta-analysis

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Figures 1-2, Tables 1-8 from Distinct Genomic Alterations in Prostate Cancers in Chinese and Western Populations Suggest Alternative Pathways of Prostate Carcinogenesis

Supporting Table 3 from A Distinct Metabolic Signature of Human Colorectal Cancer with Prognostic Potential

Supplementary Table 1 from CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy

Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts

Supporting Table 1 from A Distinct Metabolic Signature of Human Colorectal Cancer with Prognostic Potential

Supplementary Tables from A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer

Supplementary Table S3 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study

Supplementary Tables 1-5 from Comprehensive Proteogenomic Profiling Reveals the Molecular Characteristics of Colorectal Cancer at Distinct Stages of Progression

Supplementary Information from A Distinct Metabolic Signature of Human Colorectal Cancer with Prognostic Potential

Supplementary Data 2 from Generation of Prostate Tumor–Initiating Cells Is Associated with Elevation of Reactive Oxygen Species and IL-6/STAT3 Signaling

Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis.

Supplementary Data Legends and Methods from Novel Oncogene–Induced Metastatic Prostate Cancer Cell Lines Define Human Prostate Cancer Progression Signatures

Supplementary Table 1 from Novel Oncogene–Induced Metastatic Prostate Cancer Cell Lines Define Human Prostate Cancer Progression Signatures

Supplementary Table 1 from An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens as Potential Immunologic and Clinical Targets in Cancer

Supplementary Table 4 from Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer

Supplementary Table 3 from Identification of Biomarkers for Predicting Nasopharyngeal Carcinoma Response to Radiotherapy by Proteomics

Supplementary Table 1 from Identification of Biomarkers for Predicting Nasopharyngeal Carcinoma Response to Radiotherapy by Proteomics